Related Experiment Video
Updated: Mar 9, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
SPARC: As a prognostic biomarker in rectal cancer patients treated with chemo-radiotherapy
Neslihan Kurtul1, Erdem Arzu Taşdemir2, Dilek Ünal3
1Department of Radiation Oncology, Faculty of Medicine, University of Sütçü İmam, Kahramanmaras, Turkey.
Background:
The aim of this study is to search the prognostic value of SPARC expression in rectum cancer cases receiving postoperative radiotherapy.
Methods:
Forty three rectal cancer patients are recruited to this retrospective study. All patients received postoperative radiotherapy which the median dose was 5040 cGy and concomitant chemotherapy. Samples taken from their paraffin blocks were examined with immunohistochemical procedures.
Results:
When the association between SPARC expression and the clinicopathological feature was examined, there was a significant association between age and expression levels. Overall survival of patients with low expression was found to be 67 months whereas the overall survival of the patients with high expression was 32 months and the difference was statistically significant. Time to local recurrence of patients with low expression was found to be 74 months whereas time to local recurrence of the patients with high expression was 31 months. Progression free survival of the patients with low expression and high expression were 67 months and 32 months, respectively. In multivariate Cox regression analyses, high expression of SPARC was found to be associated with a statistically significant shorter overall survival and progression free survival.
Conclusions:
High expression of SPARC is related to worse prognosis in rectal cancer patients.
